Navigation Links
Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded

Armed Forces Institute for Regenerative Medicine to Develop Therapies for

Critically Injured Service Members

CLEVELAND, April 17 /PRNewswire/ -- Cleveland Clinic and Rutgers University are leading one of two civilian research consortia to develop innovative medical therapies for the treatment of wounded service members. Cleveland Clinic will receive more than $10 million from a total of $42.5 million awarded over 5 years to create a new institute called the Armed Forces Institute of Regenerative Medicine (AFIRM).

Cleveland Clinic Orthopedic Surgeon, George Muschler, M.D., is AFIRM's Co-Director, in collaboration with AFIRM Director Joachim Kohn, Ph.D., of Rutgers University. Together Drs. Muschler and Kohn will lead a collaborative network of leading clinician scientists drawn from 15 premier institutions and more than 20 commercial partners nationwide.

"The AFIRM team is deeply committed to offering new recovery options for the brave men and women who have served our country," Dr. Muschler said. "Our collaborative mission is to translate opportunities that are now available in regenerative biology as quickly as possible into practical tools that can be used on the front lines or here at home."

The mission of AFIRM is to accelerate the development of new technologies in the field of regenerative medicine and tissue engineering to effectively serve the needs of injured service members. The research and development of new therapies will focus on the regeneration of bone, muscle, tendon, nerve and blood vessels, as well as new methods for transplantation of limb and facial tissue and the treatment of burns.

Cleveland Clinic President and CEO Delos "Toby" Cosgrove has experienced the devastation of war firsthand and commends the AFIRM project.

"Early in my career, I served as an Air Force surgeon in Vietnam where I saw military casualties firsthand and witnessed the impact of combat injuries on the fine men and women of our Armed Forces," Dr. Cosgrove said. "I am honored that Cleveland Clinic is part of the team awarded this opportunity to serve these heroes and potentially help several thousands of others who suffer from similar injuries."

AFIRM is a national effort to address the healthcare challenges of severely injured service members returning from Afghanistan and Iraq, said Dr. Kohn of Rutgers.

"Our foremost goal is to alleviate the human suffering associated with debilitating blast injuries and to enable our injured men and women to return to productive lives," Dr. Kohn said.

The AFIRM will be a collaborative virtual institution working in conjunction with the US Army Institute of Surgical Research (ISR). A second AFIRM consortium will be managed by Wake Forest University Baptist Medical Center and the University of Pittsburgh who will receive another $42.5 million in funding.

Successful inter-institutional and commercial partnerships like AFIRM have become a hallmark of biotechnology in Ohio, thanks to investments made by the Ohio's Third Frontier Project (TFP), which is working to expand biotech research and business in the state. In 2005 the state initiative funded the Clinical Tissue Engineering Center (CTEC), a collaboration among Cleveland Clinic, Case Western Reserve University, University Hospitals Case Medical Center (who are also part of the Rutgers-Cleveland Clinic AFIRM team) and several other Ohio institutions and companies.

CTEC is a key partner in the larger National Center for Regenerative Medicine (NCRM), which integrates several regional programs and an international education effort focused on the development of therapies based on non-embryonic stem cells and regenerative medicine strategies.

Regenerative medicine in Ohio enjoys broad support from Ohio Governor Ted Strickland and federal government officials, including Ohio Senators George Voinovich and Sherrod Brown, Congresswoman Stephanie Tubbs Jones, and Congressman Ralph Regula.

"This extraordinary grant is a testament to the outstanding work being conducted among the partners and the Department of Defense's recognition of this work," Congressman Regula said. "I am pleased to have been an early supporter of this initiative, as I believe it will profoundly improve the lives of our service members and their families."

The core academic partners in the Rutgers-Cleveland Clinic consortium are: Case Western Reserve University, Carnegie Mellon University, Stony Brook University, Dartmouth College, MIT, Massachusetts General Hospital/Harvard Medical School, Mayo Clinic, Northwestern University, University Hospitals Case Medical Center, University of Cincinnati, University of Medicine and Dentistry of New Jersey, University of Pennsylvania, University of Virginia and Vanderbilt University.

About Cleveland Clinic

Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. Approximately 1,800 full-time salaried physicians and researchers at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2007, there were 3.5 million outpatient visits to Cleveland Clinic and 50,455 hospital admissions. Patients came for treatment from every state and from more than 80 countries. Cleveland Clinic's Web site address is .

SOURCE Cleveland Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
2. Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007
3. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
9. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
Breaking Biology Technology:
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/27/2015)... Oct. 27, 2015 In the present market ... concern for various industry verticals such as banking, healthcare, ... the growing demand for secure & simplified access control ... such as hacking of bank accounts, misuse of users, ... such as PC,s, laptops, and smartphones are expected to ...
(Date:10/26/2015)... , Oct. 26, 2015  Delta ID Inc., a ... to mobile and PC devices, announced its ActiveIRIS® technology ... arrows NX F-02H launched by NTT DOCOMO, INC in ... is the second smartphone to include iris recognition technology, ... ARROWS NX F-04G in May 2015, world,s first smartphone ...
Breaking Biology News(10 mins):